Savient Pharmaceuticals
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01739660
- Locations
- 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
- Conditions
- Gout
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT01356498
- Locations
- 🇺🇸
Kaiser Permanente Medical Center, Clinical Trials Unit, San Francisco, California, United States
🇺🇸Pacific Arthritis Center Medical Group, Santa Maria, California, United States
🇺🇸Agilence Arthritis & Osteoporosis Medical Center, Whittier, California, United States
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
- Conditions
- Chronic Gout Refractory to Conventional Therapy
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT00675103
- Locations
- 🇺🇸
University of Chicago- Dept. Biological Services, Chicago, Illinois, United States
🇺🇸The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
- Conditions
- Gout
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2011-02-28
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT00325195
- Locations
- 🇺🇸
UAB Arthritis Clinical Intervention Program, Birmingham, Alabama, United States
🇺🇸University of Arizona Arthritis Center, Tucson, Arizona, United States
🇺🇸NEA Clinic, Jonesboro, Arkansas, United States
Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients
- Conditions
- HIVPeripheral Nervous System Disorders
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2006-02-03
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT00286377
- Prev
- 1
- 2
- Next